Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Current Assets readings, the most recent being $198.7 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 25.9% to $198.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $198.7 million, a 25.9% decrease, with the full-year FY2025 number at $204.3 million, down 31.85% from a year prior.
  • Current Assets hit $198.7 million in Q4 2025 for Enanta Pharmaceuticals, down from $204.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $448.5 million in Q2 2023 to a low of $198.7 million in Q4 2025.
  • Median Current Assets over the past 5 years was $312.4 million (2022), compared with a mean of $312.6 million.
  • Biggest five-year swings in Current Assets: skyrocketed 43.26% in 2023 and later crashed 36.1% in 2024.
  • Enanta Pharmaceuticals' Current Assets stood at $327.0 million in 2021, then fell by 13.23% to $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then plummeted by 31.3% to $268.1 million in 2024, then decreased by 25.9% to $198.7 million in 2025.
  • The last three reported values for Current Assets were $198.7 million (Q4 2025), $204.3 million (Q3 2025), and $222.7 million (Q2 2025) per Business Quant data.